Clinical Trial Update: Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of amrubicin with or without Herceptin for metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Amrubicin (amrubicin)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Celgene Corporation | Conditions: Metastatic Breast Cancer | Phase 2 | Status: WITHDRAWN